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1. Introduction 
Uveal melanoma is the most common primary ocular malignancy in adults. There are about 
0.6-0.8 new patients per 100,000 inhabitants (in Europe). Several studies have demonstrated 
that complete removal of the tumour by enucleation is not advantageous compared with 
conservative therapies in terms of metastatic spread and survival.  
The primary treatment for uveal melanoma depends on many factors: size, location, 
extraocular extension, visual function, age and performance status.  
2. Enucleation 
Enucleation has been the standard treatment since the nineteenth century and is still the 
treatment of choice in large uveal melanomas.  
Enucleation is still required in a significant proportion of patients, either because the tumour 
is too extensive at presentation or because of the complications of conservative therapy. The 
procedure is performed in the surgeon’s preferred fashion. It is essential to perform 
binocular indirect ophthalmoscopy after draping the patient to confirm that the correct eye 
is being removed. The main complication specific to uveal melanoma is orbital tumour 
recurrence, which is rare. If this occurs, it is treated with local resection and external beam 
radiotherapy. It was previously believed that surgical manipulations during enucleation 
disseminated tumour cells into the vascular system, thereby causing metastatic disease; 
however, as we will see later, COMS-10 study has shown no improvement of survival after 
pre-enucleation radiotherapy, thereby casting doubt on this hypothesis. 
Globe preserving techniques include: laser photocoagulation, transpupillary thermotherapy, 
local resection, radiotherapy and gammaknife. 
Observation without treatment is a modality used for melanomas that are small and have 
dormant characteristics. Patients managed by this strategy are often asymptomatic and have 
the lesion picked up on routine ocular examination. Another subgroup of patients who may 
be managed by observation includes elderly patients with severe systemic health problems 
or short life expectancy.  
Radiotherapy (RT) offers a conservative treatment for those patients who are suitable for 
visual and motion conservation.  
3. Radiobiology 
Radiations kills a tumour either by producing free radicals that destroy cellular DNA 
immediately or by induction of mutations that go on to kill tumour cells over a protracted 
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period of time. Radiation also induces vascular fibrosis and secondary hypoxia, which again 
may take time to cause cell death. Thus, RT provides both short- and long-terms effects1.  
There are two main modalities: brachytherapy and external beam radiotherapy (that 
includes charged particles and special techniques like intensity modulated radiotherapy). 
4. Brachytherapy 
In the United States, controversies about the appropriate management of choroidal 
melanoma led to the development of the COMS (Collaborative Ocular Melanoma Study) 
group, which conducted a series of randomised studies on the use of enucleation, 
brachytherapy and radiotherapy. To date, their principal results have been that preoperative 
radiotherapy for large size melanomas does not improve survival compared with 
enucleation alone, and that there is no difference as regards survival between those patients 
treated with I-125 seed brachytherapy and those who underwent enucleation. The results of 
these studies show brachytherapy as an alternative to enucleation.  
Various materials for delivering radiation have been investigated in brachytherapy. Iodine-
125 is currently the most commonly used isotope for plaque radiotherapy of choroidal 
melanoma. Although cobalt-60, ruthenium-106, Iridium -196, strontium-90 and palladium-
103 have also been used.   
 
Radionuclide Symbol Type Energy Half-life Introduced depth 
Cobalt Co-60 Gamma/beta 1.3MeV/320Kev 5.2 years 1948  
Ruthenium Ru-106 Beta 293 KeV 373 days 1964 5 mm 
Iodine I-125 Gamma 27-35 KeV 60 days 1975  
Strontium Sr-90 Beta 546 KeV 29 years 1983 5 mm 
Iridium Ir-192 Gamma/Beta 600KeV/370 KeV 74 days 1983  
Palladium Pd-102 Gamma 21 KeV 17 days 1986  
Table 1. 
Before the COMS trials were initiated in 1986, interest in radiation therapy had increased 
because of the potential for saving the eye and perhaps some vision. 
The COMS-18 trial enrolled 1317 patients with medium size melanomas to enucleation or 
brachytherapy with iodine-125 (I-125) plaques. Six hundred and sixty were randomly 
assigned to enucleation and 657 to I-125 brachytherapy (85 Gy ). Only 2 patients in the 
enucleation arm were found to have been misdiagnosed when histopathology was centrally 
reviewed. All but 17 patients (1.3%) received the assigned treatment. Adherence to the 
brachytherapy protocol was excellent, with 91% of patients treated per protocol. Based on 
time since enrolment, 1072 patients (81%) had been followed for mortality at 5 years and 416 
(32%) at 10 years. A total of 364 patients had died: 188 (28%) of 660 patients in the 
enucleation arm and 176 (27%) of 657 patients in the brachytherapy arm. The unadjusted 
estimated 5-year survival rates were 81% and 82%, respectively; there was no clinically or 
statistically significant difference in survival rates overall (P =0.48, log-rank test). The 
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adjusted estimated risk ratio for I-125 brachytherapy vs enucleation was 0.99 (95% 
confidence interval [CI], 0.80-1.22). Five-year rates of death with histopathologically 
confirmed melanoma metastases were 11% and 9% following enucleation and 
brachytherapy respectively; after adjustment, the estimated risk ratio was 0.91 (95% CI, 0.66-
1.24). Graphs 1 and 2. They concluded that mortality rates following I-125 brachytherapy 
did not differ from mortality rates following enucleation for up to 12 years after treatment 2.   
 
 
Graph 1. Dead with melanoma metastasis at COMS-18 trial 
 
 
Graph 2. Dead from any cause at COMS-18 trial 
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Visual acuity declined in a substantial proportion of eyes in the brachytherapy group. There 
was a quadrupling of the minimum angle of resolution, or loss of 6 or more lines of visual 
acuity from baseline in 18% of patients at 1 year, 34% at 2 years and 49% at 3 years. The risk 
of vision loss was associated with a history of diabetes, thick tumours, tumours close to or 
beneath the macula, tumours with secondary retinal detachments and tumours that were 
not dome-shaped3. Secondary strabismus has also occurred in 5% of patients as a result of 
moving extraocular muscles in order to properly place the plaque to hold the radioactive 
seeds (see figure 2). 
Tumours with larger basal diameters are more likely to recur. Karlsson et al. found that 
patients with local tumour recurrence, which is likely to occur at the tumour margin, were at 
greater risk of life-threatening distant metastasis, having a 5-year survival rate of 58% 
compared with 82% for those without local recurrence. However, while local control of 
choroidal melanomas treated with brachytherapy has been reported at more than 90%, 
many treated eyes develop complications secondary to radiation delivered to adjacent 
structures. Radiation retinopathy has been identified in up to 43%. Others complications 
include optic atrophy, cystoid macular edema, cataracts, glaucoma, central retina vein 
occlusion and scleral necrosis.  
In the COMS-10 trial of preoperative radiation, patients with large tumours were 
randomized to enucleation alone or to enucleation preceded by 20 Gy of external beam 
radiation. This trial was designed to see if radiation before enucleation (removal of the eye) 
would prevent metastasis. The idea was to see if pre-operative irradiation would sterilize 
any cells that might break free during surgery.  
The two randomly assigned groups of patients were followed for at least five years or until 
death and were compared on the basis of length of remaining life and other outcomes. A 
total of 1,003 patients were enrolled; 506 were assigned to enucleation alone and 497 to pre-
enucleation radiation. With 5-year outcome known for 801 patients enrolled (80%), the 
estimated 5-year survival rates and 95% confidence intervals (CIs) were 57% (95% CI, 52% to 
62%) for enucleation alone and 62% (95% CI, 57% to 66%) for pre-enucleation radiation. 
Among the baseline covariates evaluated, only age and longest basal diameter of the 
melanoma affected the prognosis for survival to a statistically significant degree. The risk of 
death among patients treated with pre-enucleation radiation relative to those treated with 
enucleation alone after adjustment for baseline characteristics of patients, eyes, and tumours 
was 1.03 (95% CI, 0.85 to 1.25). Of 435 deaths classified by the Mortality Coding Committee, 
269 patients had histologically confirmed melanoma metastases at the time of death. 
Estimated 5-year survival rates for this secondary outcome were 72% (95% CI, 68% to 76%) 
for enucleation alone and 74% (95% CI, 69% to 78%) for pre-enucleation radiation. The 
Large-sized Choroidal Melanoma Study concluded that patients who received external 
irradiation to their eye before it was removed, had an equal chance of developing metastatic 
disease as compared to those who were treated by enucleation (removal of the eye) alone. 
This study did not find any survival difference attributable to pre-enucleation radiation of 
large choroidal melanoma, using the COMS fractionation Schedule4.  
Accrual to a nonrandomized pilot study to assess the feasibility of a randomized trial for 
small tumors was halted in 1989. Additional follow-up of these patients was carried out 
from 1994 to 1996. From December 1986 to August 1989, 204 patients with small choroidal 
melanoma, not large enough to be eligible for the COMS clinical trials, were offered 
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participation in a nonrandomized prospective follow-up study. Small choroidal melanomas 
were defined as 1.0 to 3.0 mm in apical height and at least 5.0 mm in basal diameter. A total 
of 204 patients were enrolled in the study. Patients were followed up annually through 
August 1989. Two additional assessments of treatment status and mortality were conducted 
in 1993-1994 and 1995-1996. The median length of follow-up was 92 months. Eight percent 
of patients were treated at the time of study enrolment and an additional 33% were treated 
during follow-up. Twenty-seven patients have died; 6 deaths were reported by the clinical 
center as due to metastatic melanoma. The Kaplan-Meier estimate of 5-year all-cause 
mortality was 6.0% (95% confidence interval, 2.7%-9.3%) and 8-year all-cause mortality was 
14.9% (95% confidence interval, 9.6%-20.2%). 
The study concluded that healthy patients, average age of 60 years, without a previous 
diagnosis of malignant disease who had small choroidal lesions judged to be melanoma had 
a low risk of dying within 5 years5. 
5. Implant sequence 
The procedure is performed thanks to the joint efforts of a multidisciplinary team composed 
of ophthalmologists, radiation oncologists, anaesthetists, physicists, and specialised 
radiotherapy technicians.  
Patient preparation:  
1. Placing of the radioactive plaque. This is carried out with both local and general 
anaesthetic, depending on each case, but mostly using retrobulbar anaesthesia with 
akinesis.  
2. Gestures: In general, a limbic peritomy is performed, dissecting Tenon’s capsule to 
leave the scleral surface which coincides with the tumour base exposed. If the lesion 
affects the muscle insertion area, the muscle must be disinserted.  
3. CTV (Clinical target volume) Determination: Pupilar transillumination is used for the 
localization and marking of the base of the melanoma. Various non-absorbable sutures 
are placed at the scleral level, at positions marked by an inactive phantom, in order to 
check the correct size of the proposed plaque; the definitive radioactive plaque is then 
positioned and the sutures,are tied. The diameter of the radioactive applicator should 
be 2 mm greater than the tumour base, to ensure that the microscopic disease is covered 
by a safety zone for complete irradiation of its margins. Additional margins are not 
taken to cover eye movements.  
4. Post-operative: Anti-inflammatory drugs and antibiotics are administered 
subconjuntivally, topically and systemically in theatre. The patient is subsequently 
transferred to a darkened room.  
5. Treatment course: The treatment is given as scheduled and all patients remain admitted 
to the Brachytherapy Unit. During admission, analgesic and prophylactic antibiotic 
treatment is prescribed.  
6. 6. Implant removal: On extraction of the ophthalmic plaque, the patient is again 
transferred to the implant room where it is disinserted under anaesthesia and complete 
removal of the radioactive load is checked. Once the plaque had been extracted, the 
patient returns to his room where he remains until recovery and discharge.  See figure 
1, 2 , 3 and 4. 
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Fig. 2. Target volume delineation 
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Fig. 3. Plaque with I-125 seeds. 
 
Fig. 4. Eye with the plaque in place. 
6. Prescription dose 
The prescription point is defined as the tumour apex for tumours measuring 5.0 mm or 
more in apical height; but for smaller tumours, the prescription point is 5 mm from the 
interior surface of the sclera. In 1996, the COMS adopted the recommendations of the 
American Association of Physicists in Medicine Task Group (TG-43) regarding dosimetry of 
interstitial sources in anticipation of a revised calibration standard for I-125 seeds by the 
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National Institute for Standards and Technology (NIST). Under the TG-43 formalism, the 
absorbed dose at the prescription point was 85 Gy delivered at a rate of at least 0.42 
Gy/hour, but no more than 1.05 Gy/hour. Before adopting the TG-43 formalism, the 
prescribed total dose was calculated to be 100 Gy; however, the actual amount of radiation 
delivered was not affected by the change. All dose data included in the majority of reports 
were recalculated based on the TG-43 formalism. The actual radiation dose delivered to the 
prescription point, tumour apex, sclera at the center of the plaque and critical structures 
within the eye was reported to and confirmed by the COMS Radiologic Physics Center 
(Houston, TX). Doses were calculated based on presumed plaque location, I-125 seed 
activity and location in the plaque, and times of plaque insertion and removal. 
7. Combined treatment 
Combined plaque irradiation and laser photocoagulation or thermotherapy have been used 
recently to increase the likelihood of complete local tumour destruction, particularly in 
patients with tumours adjacent to the optic disc. In 1998, Shields et al. published the results 
of 100 patients treated with plaque and transpupillary thermotherapy and found a 
recurrence rate of 3% in 8 years.  
8. Proton beam radiotherapy 
Proton-beam radiotherapy (PBRT) was first utilized in the management of uveal melanoma 
in 19756. It is now predominantly used for choroidal and ciliary body melanomas. PBRT is 
an alternative method of delivering radiation to an ocular tumour that uses charged 
particles, either protons or helium ions (PBRT). Tantalum clips are fixed to the epiescleral 
surface around the base of the tumour, and charged particles are then directed toward the 
tumour from an anterior approach. With this technique the dose is delivered in for or five 
equivalent fractions over a 7-days period. Typically a total dose of 70 Cobalt gray equivalent 
(CGE) is administered over 5 fractions. 
The density of ionization of protons increases markedly near the end of their path (Bragg 
peak). This characteristic enables accurate treatment, especially important for large lesions 
close to vital ocular structures. The advantages of charged particles include a uniform dose 
distribution throughout the treatment zone and a predictable area of treatment, since 
protons travel in a straight line and stop after a certain distance based on the initial energy 
imparted. Figure 5 
No handling of radioactive material is required by the ophthalmologist or the radiation 
oncologist dealing with PBRT, in contrast to brachytherapy where handling is required. The 
highly collimated beam of irradiation includes a 1 mm tumour margin, a 0.5 mm margin for 
patient movement and  a 1 mm margin for de penumbral effect. Seventy percent of the 
maximum radiation dose is delivered by the entrance beam as it travels through the eye 
before reaching the tumour. Therefore anterior complications including epiphora, lash loss 
and neovascular glaucoma occur more frequently with charged particles than with radiation 
delivered posteriorly7.  
As of December 2002 more than 3000 patients with uveal melanoma have been treated with 
protons at the Massachusetts General Hospital. The 5-year actuarial local control rate is 
96%for all sites within the globe, with an 80% survival rate. The probability of eye retention 
at 5 years was estimated to be 90% for the entire group and 97%, 93% and 78% for patients 
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with small, intermediate and large tumours respectively. Independent risk factors for 
enucleation were the involvement of the ciliary body, a tumour height greater than 8 mm 
and the distance between the posterior tumour edge and the fovea8. These results compare 
favourably with local control rates of 89% reported with protons in Nice, France9, and 
similar results from the Paul Scherrer Institute in Villigen, Switzerland.10 
Because some patients have experienced deteriorating vision after doses of 70 CGE, a 
randomized trial of 50 versus 70 CGE for small and intermediate-sized lesions located 
within 6 mm of the optic disc of the macula was conducted. Interim analysis of 188 patients, 
with a median follow-up of 60 months suggested no reduction in local control or survival. 
No significant improvement in visual outcomes or complications was observed. However 
visual field analysis showed a smaller mean defect in the patients randomized to 50 CGE11. 
Egger et al. reported long-term results of eye retention after treatment of uveal melanoma 
with proton beam radiotherapy12. A total of 2645 patients (2648 eyes) were treated at the 
Paul Scherrer Institute in Switzerland between 1984 and 1999. The overall eye retention rates 
at 5, 10 and 15 years after treatment were 89, 86 and 83% respectively. Enucleation was 
related to large tumour size, mainly tumour height, male gender, high intraocular pressure 
and a large degree of retinal detachment at treatment time.  
Gragoudas et al. reported that radiation maculopathy occurred in approximately 75% of 
tumours within 1 disc diameter of the fovea and in 40% of tumours greater than 1 disc 
diameter from the fovea treated with PBRT11. 
Wilson and Hungerford found local recurrence of 5.2% with PBRT. Metastatic death rates of 
12.8% at 5 years and 20.7% at 10 years were reported following PBRT13.  
9. Stereotactic radiosurgery 
Newer techniques like stereotactic radiosurgery and gammaknife radiotherapy are being 
used at some centres; however, no long-term data is available on the efficacy or 
complication rates.  
Gammaknife radiosurgery (GKR) was initially introduced to successfully treat intracranial 
lesions such as brain tumours, vascular abnormalities, skull base tumours and neurological 
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functional diseases. Gammaknife radiosurgery has been shown to be an alternative to 
enucleation for the treatment of large uveal melanomas.  
10. Methods 
10.1 Extraocular muscle sutures 
After the patient receives retrobulbar anesthesia with long-acting agents (5 cm3 of 1% 
Ropivacaine) to obtain complete akinesia, two extraocular muscles are sutured through the 
conjunctiva using 3.0 black silk suture. The two muscles are chosen according to tumour 
location to optimise globe position during treatment. 
10.2 Stereotactic lightweight aluminium frame fixation 
The stereotactic frame is attached to the patient’s head with four pins lodged in the outer 
plate of the skull. The frame provides the coordinate system for target determination by 
magnetic resonance imaging. 
10.3 Globe immobilisation and orientation 
The threads of the two sutured muscles are fixed to the stereotactic frame to immobilise and 
orientate the globe. The globe is oriented in order to localise the tumour as closely as 
possible to the centre of the stereotactic frame. This condition may reduce magnetic 
resonance image distortion. Correct globe immobilisation is crucial to performing precise 
GKR. 
10.4 Neuroimaging 
High-resolution magnetic resonance (2 mm slices) with gadolinium of the brain is 
performed, and the images are transferred to the gamma knife three-dimensional treatment 
planning system (Gamma Plan). The use of gadolinium increases the definition of tumour 
margins in the presence of subretinal fluid and retinal detachment. 
Besides the advantages of being non-invasive and easier for the patient to tolerate, 
radiosurgery provides a single day treatment that can be completed within a few hours14, 15. 
No other technique offers the same convenience for the patient. Although previous studies 
have shown GKS to be a minimally invasive, eye-saving treatment modality for uveal 
melanomas, secondary enucleation is still common with this procedure. Tumour volume 
and tumour location are thought to be major determinants of intraocular complications after 
GKS. Eagan et al. proposed that tumours of the ciliary body and tumors larger than 8 mm in 
height are more likely to require secondary enucleation after treatment. Complications of 
the treatment itself may also lead to enucleation. 
For a series of 81 patients who underwent GKS for the treatment of uveal melanoma, 
Simanová et al. achieved an 84% local tumour control rate at 10 months by applying a 
minimum dose of 31.4 Gy16. Similarly, Modorati and colleagues achieved 91% tumour 
control in a group of 78 patients treated with 30–50 Gy of radiation at the tumour periphery. 
However, they observed high complication rates, including enucleation (10.3%), retinal 
detachment (33.3%) and glaucoma (18.7%). Zehetmayer et al. used one to three fractions of 
GKS for 62 selected uveal melanoma patients, with a mean follow-up of 28.3 months, 
achieving a tumour control rate of 98%. In a previous series involving GKS, doses as high as 
70 Gy were applied to the immobilized the eye during the procedure; however, it appears 
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that the high intraocular complication rate associated with higher doses may jeopardize the 
conservative advantages of GKS. 
11. Other treatment modalities 
11.1 Trans-scleral resection 
Local trans-scleral resection has largely been abandoned in favour of more successful 
treatment methods. In 1986, Foulds and Damato recommended local resection for tumours 
of 10 to 15 mm in diameter after finding that most of the failures in their series involved 
tumours larger than 15 mm in diameter. They reported a 19% incidence of retinal 
detachment as a result of the surgery, only 41% of which responded well to repair17 ,  18. 
However, 81.1% of the eyes in the COMS showed local invasion of the sclera which the 
authors stated argued against the advisability of scleral resection as a treatment for 
choroidal melanoma due to the fact that potentially viable melanoma cells are likely to 
remain following surgery19. Proponents of transcleral resection now recommend adjuvant 
brachytherapy to irradiate any remaining tumor cells20. 
11.2 Transpupillary Thermotherapy (TTT) 
TTT uses a diode laser to deliver a beam of infrared radiation through a dilated pupil into 
an intraocular tumour in order to induce tumour cell necrosis21. 
The entire surface of the tumour is covered with overlapping treatment areas extending 1.5 
mm past the edge of the tumour into normal tissue. The advantages of TTT include 
immediate necrosis with quickly evident clinical regression, precision of treatment, and ease 
of treatment on an outpatient basis with local anesthesia. TTT causes less choroidal damage 
than plaque radiotherapy. However, TTT cannot be performed if the pupil cannot be dilated 
to allow passage of the beam, if the tumour is so peripheral that the edges are not visible, if 
opacities prevent a clear view, or if there is more than 3 mm of subretinal fluid. TTT has 
been used successfully in select cases where plaque brachytherapy has failed. TTT has also 
been combined with plaque radiotherapy in a technique called sandwich therapy, as TTT is 
maximally effective at the apex of the tumour and brachytherapy is maximally effective at 
the base 22, 23, 24. Moreover, TTT may show benefit in the treatment of hemangiomas and 
small retinoblastomas in addition to uveal melanomas. 
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